Adjuvant treatment of breast cancer patients with trastuzumab

Winer EP, Piccart-Gebhart MJ, Rugo HS, Sledge GW. Management of HER2-positive breast cancer. In: Perry MC, editor. ASCO 2006 Educational book. Alexandria, VA: ASCO; 2006. p. 3-14.Search in Google Scholar

Gennari A, Sormani MP, Puntoni M, Bruzzi P. A pooled analysis on the interaction between HER-2 expression and responsiveness of breast cancer to adjuvant chemotherapy. [Abstract 41]. Breast Cancer Res Treat 2006; 100(Suppl 1):s9.Search in Google Scholar

Lipton A, Ali SM, Leitzel K, Chinchilli V, Engle L, Harvey HA, et al. Elevated serum Her2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 1467-72.10.1200/JCO.2002.20.6.1467Search in Google Scholar

Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-74.10.1200/JCO.2005.04.173Search in Google Scholar

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.10.1056/NEJM200103153441101Search in Google Scholar

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007; 25: 118-45.10.1200/JCO.2006.09.2775Search in Google Scholar

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369: 29-36.10.1016/S0140-6736(07)60028-2Search in Google Scholar

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.10.1056/NEJMoa05212216236738Search in Google Scholar

Perez ES, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer.[Abstract 512]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25(Suppl I): 6s.10.1200/jco.2007.25.18_suppl.512Search in Google Scholar

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res and Treat 2005; 94(Suppl 1): s5.10.1158/1538-7445.SABCS15-S5-04Search in Google Scholar

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Bono P, Alanko T, Kataja V, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbin with or without trastuzumab for breast cancer. N Engl J Med 2005; 354: 789-90.Search in Google Scholar

Gelber RD. HERA trial (oral presentation); SABCS 2005.Search in Google Scholar

Paik S, Kim C, Joeng J, Geyer CE, Romond EH, Mejia-Mejia O, et al. Benefit from adjuvant trastuzumab may not be confined to patients with 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. [Abstract 511]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25(Suppl I): 5s.10.1200/jco.2007.25.18_suppl.511Search in Google Scholar

Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9.10.1200/JCO.2005.02.409116258083Search in Google Scholar